New targetable oncogenes in non-small-cell lung cancer

Geoffrey R. Oxnard, Adam Binder, Pasi A. Jänne

Research output: Contribution to journalReview article

228 Scopus citations

Abstract

The identification of oncogenic driver mutations underlying sensitivity to epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors has led to a surge of interest in identifying additional targetable oncogenes in non-small-cell lung cancer. A number of new potentially oncogenic gene alterations have been characterized in recent years, including BRAF mutations, HER2 insertions, PIK3CA mutations, FGFR1 amplifications, DDR2 mutations, ROS1 rearrangements, and RET rearrangements. In this review, we will discuss the techniques used to discover each of these candidate oncogenes, the prevalence of each in non-small-cell lung cancer, the preclinical data supporting their role in lung cancer, and data on small molecular inhibitors in development.

Original languageEnglish (US)
Pages (from-to)1097-1104
Number of pages8
JournalJournal of Clinical Oncology
Volume31
Issue number8
DOIs
StatePublished - Mar 10 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this